Financhill
Sell
28

ENOV Quote, Financials, Valuation and Earnings

Last price:
$34.57
Seasonality move :
0.27%
Day range:
$34.42 - $35.32
52-week range:
$29.32 - $53.91
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.91x
P/B ratio:
0.77x
Volume:
1.2M
Avg. volume:
933.3K
1-year change:
-37.55%
Market cap:
$2B
Revenue:
$2.1B
EPS (TTM):
-$14.29

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
ENOV
Enovis
$558.9M $0.74 4.35% 1731.46% $64.20
CATX
Perspective Therapeutics
$143.9K -$0.27 -- -35.77% $14.3929
GMED
Globus Medical
$625.9M $0.74 6.09% 580.52% $97.46
ITGR
Integer Holdings
$428.7M $1.24 6.46% 76.23% $147.88
VNRX
VolitionRX
$1.1M -$0.05 197.5% -46.88% $2.92
XTNT
Xtant Medical Holdings
$31.2M -$0.01 9.96% -33.33% $1.75
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
ENOV
Enovis
$34.60 $64.20 $2B -- $0.00 0% 0.91x
CATX
Perspective Therapeutics
$2.4700 $14.3929 $182.9M -- $0.00 0% 15.99x
GMED
Globus Medical
$71.11 $97.46 $9.8B 94.81x $0.00 0% 3.88x
ITGR
Integer Holdings
$125.59 $147.88 $4.4B 59.52x $0.00 0% 2.53x
VNRX
VolitionRX
$0.48 $2.92 $47.2M -- $0.00 0% 33.67x
XTNT
Xtant Medical Holdings
$0.51 $1.75 $70.7M -- $0.00 0% 0.58x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
ENOV
Enovis
34.16% 1.134 54.18% 0.86x
CATX
Perspective Therapeutics
-- -1.032 -- --
GMED
Globus Medical
9.6% 2.870 3.9% 1.72x
ITGR
Integer Holdings
43.46% 1.567 30% 1.99x
VNRX
VolitionRX
-28.76% 1.111 8.83% 0.19x
XTNT
Xtant Medical Holdings
44.29% -0.806 55.45% 0.94x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
ENOV
Enovis
$307.5M -$15M -18.98% -25.93% -118.48% $35.1M
CATX
Perspective Therapeutics
-- -$20.9M -- -- -- -$41.2M
GMED
Globus Medical
$393.9M $77.1M 2.31% 2.56% 11.72% $193.2M
ITGR
Integer Holdings
$120.3M $55.8M 2.85% 4.85% -0.02% $6.1M
VNRX
VolitionRX
-- -$5.8M -- -- -1217.88% -$5.5M
XTNT
Xtant Medical Holdings
$16M -$1.9M -21.41% -35.34% -6.38% -$7K

Enovis vs. Competitors

  • Which has Higher Returns ENOV or CATX?

    Perspective Therapeutics has a net margin of -125.38% compared to Enovis's net margin of --. Enovis's return on equity of -25.93% beat Perspective Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    54.82% -$12.05 $3.9B
    CATX
    Perspective Therapeutics
    -- -$0.61 --
  • What do Analysts Say About ENOV or CATX?

    Enovis has a consensus price target of $64.20, signalling upside risk potential of 85.55%. On the other hand Perspective Therapeutics has an analysts' consensus of $14.3929 which suggests that it could grow by 482.71%. Given that Perspective Therapeutics has higher upside potential than Enovis, analysts believe Perspective Therapeutics is more attractive than Enovis.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    CATX
    Perspective Therapeutics
    10 1 0
  • Is ENOV or CATX More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Perspective Therapeutics has a beta of 1.112, suggesting its more volatile than the S&P 500 by 11.175%.

  • Which is a Better Dividend Stock ENOV or CATX?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Perspective Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or CATX?

    Enovis quarterly revenues are $561M, which are larger than Perspective Therapeutics quarterly revenues of --. Enovis's net income of -$703.3M is lower than Perspective Therapeutics's net income of -$40.2M. Notably, Enovis's price-to-earnings ratio is -- while Perspective Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.91x versus 15.99x for Perspective Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.91x -- $561M -$703.3M
    CATX
    Perspective Therapeutics
    15.99x -- -- -$40.2M
  • Which has Higher Returns ENOV or GMED?

    Globus Medical has a net margin of -125.38% compared to Enovis's net margin of 4.03%. Enovis's return on equity of -25.93% beat Globus Medical's return on equity of 2.56%.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    54.82% -$12.05 $3.9B
    GMED
    Globus Medical
    59.92% $0.19 $4.6B
  • What do Analysts Say About ENOV or GMED?

    Enovis has a consensus price target of $64.20, signalling upside risk potential of 85.55%. On the other hand Globus Medical has an analysts' consensus of $97.46 which suggests that it could grow by 37.06%. Given that Enovis has higher upside potential than Globus Medical, analysts believe Enovis is more attractive than Globus Medical.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    GMED
    Globus Medical
    6 4 0
  • Is ENOV or GMED More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Globus Medical has a beta of 1.324, suggesting its more volatile than the S&P 500 by 32.371%.

  • Which is a Better Dividend Stock ENOV or GMED?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Globus Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Globus Medical pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or GMED?

    Enovis quarterly revenues are $561M, which are smaller than Globus Medical quarterly revenues of $657.3M. Enovis's net income of -$703.3M is lower than Globus Medical's net income of $26.5M. Notably, Enovis's price-to-earnings ratio is -- while Globus Medical's PE ratio is 94.81x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.91x versus 3.88x for Globus Medical. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.91x -- $561M -$703.3M
    GMED
    Globus Medical
    3.88x 94.81x $657.3M $26.5M
  • Which has Higher Returns ENOV or ITGR?

    Integer Holdings has a net margin of -125.38% compared to Enovis's net margin of -5.14%. Enovis's return on equity of -25.93% beat Integer Holdings's return on equity of 4.85%.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    54.82% -$12.05 $3.9B
    ITGR
    Integer Holdings
    27.51% -$0.66 $2.8B
  • What do Analysts Say About ENOV or ITGR?

    Enovis has a consensus price target of $64.20, signalling upside risk potential of 85.55%. On the other hand Integer Holdings has an analysts' consensus of $147.88 which suggests that it could grow by 17.74%. Given that Enovis has higher upside potential than Integer Holdings, analysts believe Enovis is more attractive than Integer Holdings.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    ITGR
    Integer Holdings
    6 2 0
  • Is ENOV or ITGR More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Integer Holdings has a beta of 1.030, suggesting its more volatile than the S&P 500 by 3.045%.

  • Which is a Better Dividend Stock ENOV or ITGR?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Integer Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Integer Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or ITGR?

    Enovis quarterly revenues are $561M, which are larger than Integer Holdings quarterly revenues of $437.4M. Enovis's net income of -$703.3M is lower than Integer Holdings's net income of -$22.5M. Notably, Enovis's price-to-earnings ratio is -- while Integer Holdings's PE ratio is 59.52x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.91x versus 2.53x for Integer Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.91x -- $561M -$703.3M
    ITGR
    Integer Holdings
    2.53x 59.52x $437.4M -$22.5M
  • Which has Higher Returns ENOV or VNRX?

    VolitionRX has a net margin of -125.38% compared to Enovis's net margin of -1226.82%. Enovis's return on equity of -25.93% beat VolitionRX's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    54.82% -$12.05 $3.9B
    VNRX
    VolitionRX
    -- -$0.07 -$17.8M
  • What do Analysts Say About ENOV or VNRX?

    Enovis has a consensus price target of $64.20, signalling upside risk potential of 85.55%. On the other hand VolitionRX has an analysts' consensus of $2.92 which suggests that it could grow by 509.17%. Given that VolitionRX has higher upside potential than Enovis, analysts believe VolitionRX is more attractive than Enovis.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    VNRX
    VolitionRX
    2 1 0
  • Is ENOV or VNRX More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison VolitionRX has a beta of 0.997, suggesting its less volatile than the S&P 500 by 0.339%.

  • Which is a Better Dividend Stock ENOV or VNRX?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. VolitionRX pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or VNRX?

    Enovis quarterly revenues are $561M, which are larger than VolitionRX quarterly revenues of $474.5K. Enovis's net income of -$703.3M is lower than VolitionRX's net income of -$5.8M. Notably, Enovis's price-to-earnings ratio is -- while VolitionRX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.91x versus 33.67x for VolitionRX. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.91x -- $561M -$703.3M
    VNRX
    VolitionRX
    33.67x -- $474.5K -$5.8M
  • Which has Higher Returns ENOV or XTNT?

    Xtant Medical Holdings has a net margin of -125.38% compared to Enovis's net margin of -10.04%. Enovis's return on equity of -25.93% beat Xtant Medical Holdings's return on equity of -35.34%.

    Company Gross Margin Earnings Per Share Invested Capital
    ENOV
    Enovis
    54.82% -$12.05 $3.9B
    XTNT
    Xtant Medical Holdings
    50.85% -$0.02 $77.1M
  • What do Analysts Say About ENOV or XTNT?

    Enovis has a consensus price target of $64.20, signalling upside risk potential of 85.55%. On the other hand Xtant Medical Holdings has an analysts' consensus of $1.75 which suggests that it could grow by 244.42%. Given that Xtant Medical Holdings has higher upside potential than Enovis, analysts believe Xtant Medical Holdings is more attractive than Enovis.

    Company Buy Ratings Hold Ratings Sell Ratings
    ENOV
    Enovis
    7 1 0
    XTNT
    Xtant Medical Holdings
    2 0 0
  • Is ENOV or XTNT More Risky?

    Enovis has a beta of 1.583, which suggesting that the stock is 58.325% more volatile than S&P 500. In comparison Xtant Medical Holdings has a beta of -0.124, suggesting its less volatile than the S&P 500 by 112.425%.

  • Which is a Better Dividend Stock ENOV or XTNT?

    Enovis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Enovis pays -- of its earnings as a dividend. Xtant Medical Holdings pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios ENOV or XTNT?

    Enovis quarterly revenues are $561M, which are larger than Xtant Medical Holdings quarterly revenues of $31.5M. Enovis's net income of -$703.3M is lower than Xtant Medical Holdings's net income of -$3.2M. Notably, Enovis's price-to-earnings ratio is -- while Xtant Medical Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Enovis is 0.91x versus 0.58x for Xtant Medical Holdings. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    ENOV
    Enovis
    0.91x -- $561M -$703.3M
    XTNT
    Xtant Medical Holdings
    0.58x -- $31.5M -$3.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Is Palantir Stock a Millionaire Maker?
Is Palantir Stock a Millionaire Maker?

Palantir (NASDAQ:PLTR) has shot upward over the last year and…

Is QuantumScape a Buy Now?
Is QuantumScape a Buy Now?

QuantumScape (NYSE:QS) is an innovative EV battery company that specializes…

Is Vertex Stock Still a Good Buy?
Is Vertex Stock Still a Good Buy?

Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…

Stock Ideas

Sell
50
Is AAPL Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 35x

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Buy
59
Is NVDA Stock a Buy?

Market Cap: $2.7T
P/E Ratio: 38x

Alerts

Buy
62
RGC alert for May 2

Regencell Bioscience Holdings [RGC] is up 20.58% over the past day.

Sell
36
WGS alert for May 2

GeneDx Holdings [WGS] is down 6.85% over the past day.

Sell
42
VICR alert for May 2

Vicor [VICR] is down 1.28% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock